(EMAILWIRE.COM, January 05, 2022 ) The use of mHealth for the diagnosis of rhinitis is currently limited, with a small number of mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals. Recent developments in integrated biosensors, wireless communication, and power harvesting techniques generate a new breed of point-of-care devices. However, AR is a very common disease. Any diagnostic device connected to a smartphone (e.g., peak nasal inspiratory flow meters or intranasal biosensors) would need to be inexpensive to be affordable.

According to the new market research report "Allergy Diagnostics Market by Product & Service (Consumables, Instruments (Immunoassay Analyzer, ELISA Analyzer, Luminometer), Service), Allergen (Food, Inhaled, Drug), Test Type (In Vivo, In Vitro), End User (Diagnostic Laboratories) – Global Forecast to 2026", published by MarketsandMarkets™, the Allergy Diagnostics Market is projected to reach USD 8.2 billion by 2026 from USD 4.8 billion in 2021, at a CAGR of 11.1% from 2021 to 2026.

Key Developments:

- In 2021, Hitachi Chemical Diagnostics, Inc. has been renamed Minaris Medical America, Inc. By uniting the medical business group companies under the name of Minaris Medical, Hitachi aims to strengthen its global presence and expand business operations in the field of in-vitro diagnostics. The companies are a part of Showa Denko Materials Co., Ltd. (renamed from Hitachi Chemical Co., Ltd. on Oct 1, 2020).

- In 2021, PerkinElmer Inc. entered into an agreement with Immunodiagnostic Systems Holdings PLC to acquire the later. The acquisition will enable PerkinElmer Inc. to strengthen its position in the ImmunoDiagnostics (IDS) market. IDS would be incorporated under EUROIMMUN Medizinische LABORDIAGNOSTIKA AG, a company offering allergy products and solutions.

- In 2020, NEOGEN Corporation launched Reveal 3-D for Gluten

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=232871701

"Consumables are expected to hold the largest share of the allergy diagnostics market, by product & service in 2021."

Based on product & service, the market is segmented into consumables, instruments, and services. In 2020, the consumables segment accounted for the largest share of the market. The large share of the consumables segment can be attributed to the increasing cases of allergies and the need for rapid tests to diagnose allergic conditions. The consumables segment is also expected to witness significant growth during the forecast period.

"In vivo tests are expected to hold the largest share of the market, by test type in 2021."

Based on test type, the allergy diagnostics market is segmented into in vivo tests and in vitro tests. In 2020, the in vivo tests segment accounted for the largest share of the market. The growth of this segment is mainly driven by the increasing adoption of various in vivo tests, such as skin prick tests. These tests are dependable, safe, convenient, and cost-effective, as compared to in vitro tests.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=232871701

"Inhaled allergens are expected to hold the largest share of the market, by allergen in 2021."

Based on allergens, the allergy diagnostics market is segmented into inhaled allergens, food allergens, drug allergens, and other allergens. In 2020, the inhaled allergens segment accounted for the largest share of the market due to the increasing environmental pollution and rising pollen coupled with other factors such as fungus, mold, and dust.

"Diagnostic laboratories are expected to hold the largest share of the allergy diagnostics market, by end user in 2021."

Based on end user, the market is segmented into diagnostic laboratories, hospital-based laboratories, academic research institutes, and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the market. The large share of the segment can be primarily attributed to the preference for proper diagnosis from a specialist, rising awareness regarding the management of allergic diseases, and the availability of funds for the operation of independent diagnostic laboratories.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=232871701

"North America commanded the largest share of the allergy diagnostics market in 2021."

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America commanded the largest share of the market. The large share of North America can be attributed to the rising incidence of allergies, favorable reimbursement scenarios for allergy diagnosis, and the availability of supportive initiatives by associations.

The major players operating in this allergy diagnostics market are Thermo Fisher Scientific Inc., (US), Siemens Healthineers (Germany), Danaher (US), Omega Diagnostics Group PLC (UK), bioMérieux SA (France), Romer Labs Division Holding (Austria), EUROIMMUN Medizinische Labordiagnostika AG (Germany), HollisterStier Allergy (US), NEOGEN Corporation (US), Eurofins Scientific (Luxembourg), Minaris Medical America, Inc. (US), Stallergenes Greer (UK), HOB Biotech Group Corp., Ltd. (China), HYCOR Biomedical (US), R-Biopharm AG (Germany), AESKU.GROUP GmbH (Germany), ACON Laboratories, Inc. (US), Lincoln Diagnostics, Inc. (US), Astra Biotech GmbH (Germany), and Erba Group (UK).